Retia has created a new, less-invasive system to monitor cardiac outpt (CO) and other key hemodynamic parameters accurately when patients go unstable. By monitoring changes in CO, clinicians can detect, diagnose and treat life-threatening conditions better, leading to improved outcomes and lower costs. The patented platform technology behind Retia's monitor was licensed exclusively from Michigan State and MIT.
The Retia Monitor connects to existing radial arterial catheters, which are routinely placed in high-risk patients in the OR and ICU (95% of the time in the US).
The Retia Monitor offers early detection of changes in CO by processing existing peripheral blood pressure signals using a proprietary algorithm. This approach is called "pulse contour analysis." Retia's algorithm models blood circulation and accounts for beat-to-beat variations in the blood pressure signal. These variations, ignored in other pulse contour algorithms, turn out to be critical to the calculation of CO. Retia also uses additional non-invasive sensors to help the monitor to maintain its accuracy during severe vasodilation or vasoconstriction. Other competing system are actually contraindicated during these situations and have been shown to fail dramatically in numerous, clinically-relevant situations. The Retia algorithm has been validated in animals across a wide range of hemodynamic conditions and in over 300 human subjects, including the critically ill.
•12.9% calibrated CO error compared to aortic flow probe in 6 animals during drug and volume interventions
[IEEE Trans Biomed Eng, 53(3):459, 2006]
•15.1% calibrated CO error compared to Doppler ultrasound in 10 healthy humans during drug and postural interventions
[J Appl Physiol, 101:598, 2006]
•Reliable tracking of CO reductions in 129 healthy humans during central hypovolemia
[Br J Anaesth, 106(1):23, 2011]
•18.5% calibrated CO error compared to pulmonary artery catheter (single bolus thermodilution) in 184 critically ill patients
[Br J Anaesth, doi: 10.1093/bja/aes099, 2012]
By comparison current products have large failures in key clinical situations including:
3. End stage liver failure and liver transplants - these have large fluid shifts and other hemodynamic changes
5. Post-op high-risk surgery